Overview
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
Status:
Completed
Completed
Trial end date:
2009-05-01
2009-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Several psychiatric adverse events (eg, depression, fatigue, psychoses, behavior troubles, anxiety, irritability, deteriorated concentration, and insomnia) that are likely to occur during the treatment course with PegIntron plus Rebetol may prompt patients to discontinue their treatment early. The goal of this study is to assess whether a psychotherapy support program may contribute to a better adherence rate.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Interferon-alpha
Peginterferon alfa-2b
Ribavirin
Criteria
Inclusion Criteria:- Adult patients with hepatitis C
Exclusion Criteria:
- According to the products' labeling